LLY

1,152.41

-2.04%↓

JNJ

231.8

-0.62%↓

ABBV

223.9

-0.76%↓

UNH

410.6

+2.54%↑

MRK

118.89

-2.67%↓

LLY

1,152.41

-2.04%↓

JNJ

231.8

-0.62%↓

ABBV

223.9

-0.76%↓

UNH

410.6

+2.54%↑

MRK

118.89

-2.67%↓

LLY

1,152.41

-2.04%↓

JNJ

231.8

-0.62%↓

ABBV

223.9

-0.76%↓

UNH

410.6

+2.54%↑

MRK

118.89

-2.67%↓

LLY

1,152.41

-2.04%↓

JNJ

231.8

-0.62%↓

ABBV

223.9

-0.76%↓

UNH

410.6

+2.54%↑

MRK

118.89

-2.67%↓

LLY

1,152.41

-2.04%↓

JNJ

231.8

-0.62%↓

ABBV

223.9

-0.76%↓

UNH

410.6

+2.54%↑

MRK

118.89

-2.67%↓

Kodu・Aktsiate loetelu・Denali Therapeutics Inc

Denali Therapeutics Inc

Suletud

SektorTervishoid

20.27 5.57

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

19.17

Max

19.66

Põhinäitajad
By Trading Economics
Sissetulek	102K -128M
Aktsiakasum	-0.69
Töötajad	507
EBITDA	-9.8M -135M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+81.86% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. aug 2026

Turustatistika
By TradingEconomics
Turukapital	277M 3.2B
Eelmine avamishind	14.7
Eelmine sulgemishind	20.27

Uudiste sentiment

By Acuity

27%

73%

71 / 344 Pingereas Healthcare

Denali Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. juuni 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8. juuni 2026, 15:41 UTC

Suurimad hinnamuutused turgudel

American Battery Shares Jump on Energy Department Victory

8. juuni 2026, 23:46 UTC

Market Talk

Nikkei May Rebound After Monday's Selloff -- Market Talk

8. juuni 2026, 23:37 UTC

Market Talk

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8. juuni 2026, 23:25 UTC

Market Talk

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8. juuni 2026, 23:25 UTC

Market Talk

Global Equities Roundup: Market Talk

8. juuni 2026, 21:57 UTC

Omandamised, ülevõtmised, äriostud

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8. juuni 2026, 21:56 UTC

Omandamised, ülevõtmised, äriostud

Salesforce Agrees to Buy m3ter

8. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8. juuni 2026, 19:22 UTC

Market Talk

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8. juuni 2026, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8. juuni 2026, 18:52 UTC

Market Talk

Global Energy Roundup: Market Talk

8. juuni 2026, 18:52 UTC

Market Talk

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8. juuni 2026, 18:17 UTC

Market Talk

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8. juuni 2026, 17:32 UTC

Market Talk

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8. juuni 2026, 17:29 UTC

Market Talk

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8. juuni 2026, 17:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. juuni 2026, 16:55 UTC

Omandamised, ülevõtmised, äriostud

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8. juuni 2026, 16:54 UTC

Omandamised, ülevõtmised, äriostud

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8. juuni 2026, 16:40 UTC

Market Talk

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8. juuni 2026, 16:31 UTC

Market Talk

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8. juuni 2026, 16:27 UTC

Market Talk

Mexican Inflation Seen Easing in May -- Market Talk

8. juuni 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. juuni 2026, 16:03 UTC

Omandamised, ülevõtmised, äriostud

Orange Bought Stake From Lorca

8. juuni 2026, 16:01 UTC

Omandamised, ülevõtmised, äriostud

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8. juuni 2026, 16:01 UTC

Omandamised, ülevõtmised, äriostud

Orange Acquires 100% Ownership of MasOrange

8. juuni 2026, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

8. juuni 2026, 15:58 UTC

Market Talk

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8. juuni 2026, 15:55 UTC

Market Talk

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8. juuni 2026, 15:41 UTC

Market Talk

Gold Falls Below 200-Day Moving Average -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Denali Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

81.86% tõus

12 kuu keskmine prognoos

Keskmine 35.5 USD 81.86%

Kõrge 42 USD

Madal 23 USD

Põhineb 13 Wall Streeti analüütiku instrumendi Denali Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

13 ratings

Osta

Hoia

Müü

Põhineb 13 analüütiku instrumendi Denali Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

71 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.